Vericel Corp [VCEL] stock is trading at $35.32, up 1.64%. An important factor to consider is whether the stock is rising or falling in short-term value. The VCEL shares have gain 10.89% over the last week, with a monthly amount glided 10.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vericel Corp [NASDAQ: VCEL] stock has seen the most recent analyst activity on September 17, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, Canaccord Genuity started tracking the stock with Buy rating on August 09, 2024, and set its price target to $57. On June 20, 2024, TD Cowen initiated with a Buy rating and assigned a price target of $55 on the stock. Truist upgraded its rating to a Buy and increased its price target to $51 on January 25, 2024. BTIG Research upgraded its rating to a Buy but $39 remained the price target by the analyst firm on August 08, 2023. BTIG Research downgraded its rating to Neutral for this stock on November 10, 2022. In a note dated November 09, 2022, Truist downgraded an Hold rating on this stock.
Vericel Corp [VCEL] stock has fluctuated between $29.24 and $63.00 over the past year. Currently, Wall Street analysts expect the stock to reach $41 within the next 12 months. Vericel Corp [NASDAQ: VCEL] shares were valued at $35.32 at the most recent close of the market. An investor can expect a potential return of 16.08% based on the average VCEL price forecast.
Analyzing the VCEL fundamentals
Vericel Corp [NASDAQ:VCEL] reported sales of 249.12M for the trailing twelve months, which represents a growth of 20.09%. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at 0.0%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.03%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.02 and Total Capital is 0.0. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.38 points at the first support level, and at 33.44 for the second support level. However, for the 1st resistance point, the stock is sitting at 35.79, and for the 2nd resistance point, it is at 36.26.
Ratios To Look Out For
For context, Vericel Corp’s Current Ratio is 4.97. On the other hand, the Quick Ratio is 4.56, and the Cash Ratio is 1.96. Considering the valuation of this stock, the price to sales ratio is 7.15, the price to book ratio is 5.81 and price to earnings (TTM) ratio is 283.24.
Transactions by insiders
Recent insider trading involved Hopper Jonathan Mark, Chief Medical Officer, that happened on Sep 02 ’25 when 10000.0 shares were sold. Officer, Hopper Jonathan Mark completed a deal on Sep 02 ’25 to buy 10000.0 shares. Meanwhile, Director MCLAUGHLIN KEVIN F sold 7000.0 shares on Aug 06 ’25.
